Biohit Oyj

Board/Management Information • Jul 31, 2012

Changes to Biohit Oyj’s management

Changes to Biohit Oyj’s management

Biohit Oyj Changes to Biohit Oyj´s management 31 July 2012 9:00 a.m.

Biohit Oyj's Chief Financial Officer (CFO) Jussi Kolunen's responsibilities
have been broadened to include also as corporate communications

Biohit's Management Team now includes the following members and functions:

Semi Korpela, CEO
Jussi Kolunen, Finance, HR and Communications
Anu Mickels, Sales and Marketing
Panu Hendolin, Research and Product Development
Tapani Tiusanen, Operations and ICT
Lea Paloheimo, Development and Quality

Semi Korpela, M.Sc. (Econ.)
CEO, Biohit Group
Tel.: +358 9 773 861
Mobile: +358 40 573 7701
semi.korpela@biohit.fi
BIOHIT Healthcare
Innovating for Health

Distribution:
NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press

www.biohithealthcare.com

About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company that was
established in 1988. The company's mission is to improve human health and
quality of life. Biohit specialises in products and systems that promote the
diagnosis and prevention of diseases of the gastrointestinal tract.

Innovations and patents
The company follows a goal-directed and long-term innovation and patenting
strategy with scientific communities. New technology based on research results
and innovations is used to produce new solutions for medical science and
research institutions in order to promote research and people's wellbeing.

Diagnostics
The diagnostics business comprises products and analysis systems for the early
diagnosis of gastrointestinal diseases, such as the blood sample-based
GastroPanel examinations for the diagnosis of stomach diseases and their
associated risks; quick tests for the diagnosis of lactose intolerance and H.
pylori infection in connection with gastroscopy; and the ColonView examination
for the early detection of intestinal bleeding that indicates a risk of
colorectal cancer. Biohit's Acetium reduces the amount of carcinogenic
acetaldehyde in an anacidic stomach.

The Biohit Group
The Group employs about 35 people. Biohit is headquartered in Helsinki and the
company has a subsidiary in the UK. Biohit's products are also sold globally
through numerous distributors.
Biohit is headquartered in Helsinki and the company has a subsidiary in the UK.
Since 1999, Biohit's Series B share has been quoted on NASDAQ OMX Helsinki in
the Small cap/Healthcare group. It is traded under the code BIOBV

(www.biohit.com/investors).